MetaCap

Anixa Biosciences (ANIX) vs TuHURA Biosciences (HURA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

TuHURA Biosciences (HURA) has outperformed Anixa Biosciences (ANIX) over the past year, losing 28.2% versus a loss of 43.8%. Over five years, ANIX leads with a -38.7% price change compared with -99.9% for HURA. Anixa Biosciences is the larger company by market cap ($84.8 million vs $82.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANIX-43.78%HURA-28.16%
+89%+3%-83%
Nov 21, 20251 yearNov 20, 2026
ANIX-40.92%HURA-99.91%
+52%-28%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANIX versus HURA key metrics
MetricANIXHURA
Share price$2.44$1.25
Market cap$84.82M$82.20M
1-day change-6.15%-8.09%
YTD return-21.79%+65.13%
1-year return-43.78%-28.16%
5-year return-38.69%-99.91%
EPS (TTM)$-0.32$-0.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-10.93M$-30.05M
52-week high$5.46$3.43
52-week low$2.32$0.41
Distance from 52-week high-55.31%-63.56%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+296.31%+543.20%
Average volume282.29K329.76K
Shares outstanding34.76M65.76M
Employees422
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • HURA has outperformed ANIX by 15.6 percentage points over the past year.

About Anixa Biosciences

ANIX stock →

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About TuHURA Biosciences

HURA stock →

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.

Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees

ANIX vs HURA FAQ

Which is bigger, Anixa Biosciences or TuHURA Biosciences?

Anixa Biosciences (ANIX) is larger, with a market capitalization of $84.82M compared with $82.20M for TuHURA Biosciences (HURA).

Which stock has performed better over the past year, ANIX or HURA?

HURA returned -28.16% over the past 12 months, compared with -43.78% for ANIX (price return, excluding dividends). Past performance does not predict future results.

Are Anixa Biosciences and TuHURA Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons